Pharmaceuticals & Therapeutics

After a 1,000% stock surge on promising clinical data, Nektar Therapeutics secures $460M, fueling its next chapter in immunotherapy amid high hopes and risks.

Elanco's founding chairman and innovation head are leaving, marking a pivotal leadership shift as the animal health giant charts its post-spin-off future.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

With a $15 million funding boost, Nasus Pharma is accelerating its powder-based intranasal epinephrine, NS002, challenging the EpiPen's dominance.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

The firm behind a controversial drug-permissive sporting event is hitting Wall Street via a SPAC, challenging the ethics of global anti-doping standards.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

A new 'longevity center' in Naperville signals a growing trend in proactive health, but what does this mean for the Chicago wellness landscape?

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

Helsinki pioneers a revolutionary cancer therapy, offering new hope with a targeted neutron beam that destroys tumors in just one or two sessions.

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

A new plant-derived drug shows promise in preventing prostate cancer and improving cholesterol, but the company faces significant financial hurdles ahead.

The Norwegian drugmaker posted all-time high revenue and EBITDA for 2025, signaling resilience and a strategic pivot to future growth beyond metformin.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

A 'world-first' cervical implant from Zavation Medical Products combines two materials to enhance bone growth while maintaining critical imaging capabilities.